CINECA IRIS Institutional Research Information System

LOUPAKIS, FOTIOS
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.348
AS - Asia 3.298
EU - Europa 2.077
SA - Sud America 753
AF - Africa 181
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 5
Totale 13.669
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.173
SG - Singapore 1.026
CN - Cina 774
HK - Hong Kong 673
BR - Brasile 606
VN - Vietnam 420
IT - Italia 382
DE - Germania 304
SE - Svezia 288
BG - Bulgaria 215
GB - Regno Unito 185
FR - Francia 183
RU - Federazione Russa 140
CA - Canada 129
FI - Finlandia 92
IN - India 72
AT - Austria 70
TR - Turchia 68
CI - Costa d'Avorio 65
AR - Argentina 52
JP - Giappone 51
BD - Bangladesh 40
NL - Olanda 38
ID - Indonesia 33
ES - Italia 32
SN - Senegal 31
EC - Ecuador 27
NG - Nigeria 26
UA - Ucraina 24
IQ - Iraq 23
MX - Messico 23
PL - Polonia 21
SA - Arabia Saudita 20
ZA - Sudafrica 20
CL - Cile 18
VE - Venezuela 16
PK - Pakistan 15
CO - Colombia 13
CZ - Repubblica Ceca 11
BE - Belgio 10
LT - Lituania 10
PT - Portogallo 10
MA - Marocco 9
MY - Malesia 9
IL - Israele 8
NO - Norvegia 8
PY - Paraguay 8
CH - Svizzera 7
NP - Nepal 7
PE - Perù 7
TW - Taiwan 7
AZ - Azerbaigian 6
TN - Tunisia 6
UZ - Uzbekistan 6
AL - Albania 5
EG - Egitto 5
IE - Irlanda 5
KE - Kenya 5
RO - Romania 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
EU - Europa 4
HN - Honduras 4
HU - Ungheria 4
KR - Corea 4
NZ - Nuova Zelanda 4
OM - Oman 4
SI - Slovenia 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
BJ - Benin 3
BO - Bolivia 3
CR - Costa Rica 3
EE - Estonia 3
IR - Iran 3
JM - Giamaica 3
LB - Libano 3
PA - Panama 3
UY - Uruguay 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
GE - Georgia 2
KZ - Kazakistan 2
LV - Lettonia 2
MK - Macedonia 2
MT - Malta 2
NI - Nicaragua 2
PH - Filippine 2
PS - Palestinian Territory 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
Totale 13.654
Salva come PNG Salva come JPEG
Città #
Woodbridge 848
Ashburn 696
Fairfield 695
Hong Kong 655
Houston 542
Singapore 535
Santa Clara 478
Ann Arbor 474
Seattle 317
Chandler 306
San Jose 257
Cambridge 250
Wilmington 242
Sofia 215
Dallas 210
Shanghai 200
Beijing 196
Boardman 169
New York 166
Ho Chi Minh City 109
Princeton 96
Lawrence 90
Lauterbourg 89
Ottawa 79
Des Moines 73
Los Angeles 71
Hanoi 69
Medford 65
Abidjan 63
Vienna 60
Dearborn 57
São Paulo 57
Florence 47
Lancaster 43
Istanbul 42
Düsseldorf 41
Nanjing 41
Redondo Beach 41
Tokyo 39
Pisa 38
Council Bluffs 36
Serra 35
London 34
Frankfurt am Main 33
Helsinki 32
Buffalo 31
Dakar 31
Dong Ket 31
San Diego 30
Bremen 27
Lagos 26
Phoenix 25
Redwood City 24
Rio de Janeiro 24
Munich 23
Ogden 22
Positano 19
Rome 19
Warsaw 17
Changsha 16
Chicago 16
Montreal 16
Kunming 15
Shenyang 15
Boulder 14
Nanchang 14
Nuremberg 14
Seacroft 14
Toronto 14
Belo Horizonte 13
Columbus 13
Da Nang 13
Jakarta 13
San Francisco 13
Atlanta 12
Brasília 12
Hefei 12
Marseille 12
New Delhi 12
Hebei 11
Orem 11
Haiphong 10
Johannesburg 10
Paris 10
Quito 10
Valencia 10
Baghdad 9
Curitiba 9
Detroit 9
Denver 8
Madrid 8
Milan 8
Poplar 8
Brussels 7
Bắc Ninh 7
Fuzhou 7
Izmir 7
Jacksonville 7
Jeddah 7
Oslo 7
Totale 9.733
Salva come PNG Salva come JPEG
Nome #
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 325
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 277
European Guide on Quality Improvement in Comprehensive Cancer Control 277
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 251
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 219
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 218
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 208
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 192
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials 191
TAS-102 for the treatment of metastatic colorectal cancer 184
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 178
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 178
Quantitative evidence for early metastatic seeding in colorectal cancer 173
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer 170
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 170
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 169
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 169
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. 168
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 168
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients 167
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 167
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. 166
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 166
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 165
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 and TRIBE trials 165
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 165
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3 164
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer 163
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 162
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy 159
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 159
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer 158
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 158
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 157
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 157
BRAF-mutated metastatic colorectal cancer between past and future 155
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 152
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients. 149
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 145
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy 145
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 143
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 142
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 142
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 141
Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer 141
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 140
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 139
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 138
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 137
Clinical significance of tlr1 i602s polymorphism for patients with metastatic colorectal cancer treated with folfiri plus bevacizumab 137
Polymorphisms in genes involved in EGFR turnover are predictive for cetuximab efficacy in colorectal cancer 133
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 133
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 132
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 132
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 132
Body mass index is prognostic in metastatic colorectal cancer: Pooled analysis of patients from first-line clinical trials in the ARCAD database 130
null 129
prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 126
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. 126
Epstein-Barr virus associated gastric dysplasia: a new rare entity? 125
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 124
Quantitative evidence for early metastatic seeding in colorectal cancer 123
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis 122
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 122
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial 121
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer 121
Da Vinci Xi Full Robotic Colorectal Resections with Other Major Oncological Surgical Procedures: Preliminary Experience 120
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 119
Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer 116
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 115
Upfront chemotherapy regimens in unresectable disease: one, two, or three cytotoxics? 111
null 111
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 109
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 109
Pharmacogenomics of cetuximab in metastatic colorectal cancer. 107
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 107
Folfoxiri and bevacizumab for metastatic colorectal cancer. 106
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy 102
Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer (CRC) 101
null 98
Adjuvant sistemy chemotherapy after putative curative resection of colorectal liver and lung metastases. 96
DPYD c.1905+1G>A and c.2846 A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer. 92
null 90
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 89
null 85
null 83
First-line chemotherapy for mCRC-a review and evidence-based algorithm 82
FIRST EXPERIENCE IN COLORECTAL SURGERY WITH THE NEW INTEGRATED TABLE MOTION FOR THE DA VINCI XI SURGICAL SYSTEM 81
null 73
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 71
Pharmacogentic concerns in metastatic colorectal cancer therapy. 71
null 69
null 68
Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis 68
null 65
A perspective on the current management of advanced colorectal cancer 64
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: Results from phase III TRIBE trial by the gruppo oncologico del nord ovest 64
null 62
null 60
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. 58
Totale 13.682
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.496
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.496
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021144 0 0 0 0 0 0 0 0 0 0 0 144
2021/2022937 19 53 16 37 171 152 22 31 59 75 33 269
2022/20231.107 124 166 80 101 112 147 16 57 221 4 76 3
2023/2024640 49 46 96 7 103 103 51 23 17 6 52 87
2024/20252.797 19 97 72 109 335 333 209 129 277 412 255 550
2025/20263.421 163 386 414 438 349 323 448 195 214 284 142 65
Totale 13.927